# Study on resistance mechanisms and molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa to ceftazidime/avibactam in a certain region of China

**Authors:** Xiaohan Qiao, He Zhang, Yao Xu, Ting Cao, Ruobing Wang, Xinyu Deng, Wei Liang, Lin Zheng

PMC · DOI: 10.3389/fcimb.2025.1643755 · Frontiers in Cellular and Infection Microbiology · 2025-10-21

## TL;DR

This study examines why some Pseudomonas aeruginosa bacteria in China resist a specific antibiotic combination, finding that factors like genetic changes and biofilm formation play a role.

## Contribution

The study identifies novel resistance mechanisms and clonal spread of ceftazidime/avibactam-resistant Pseudomonas aeruginosa in a specific Chinese region.

## Key findings

- Ceftazidime/avibactam resistance in Pseudomonas aeruginosa is linked to blaNDM carriage, biofilm formation, and efflux pump overexpression.
- The ST1076 clone is prevalent among resistant isolates and spreads via horizontal gene transfer.
- Resistant isolates show higher recurrence and lower clinical improvement compared to susceptible isolates.

## Abstract

Carbapenem-resistant Pseudomonas aeruginosa(CRPA) poses a serious threat in healthcare settings due to its multidrug resistance and high mortality. Although ceftazidime/avibactam (CZA) demonstrates potent activity against CRPA, resistance has emerged.

This study investigates the epidemiology and molecular mechanisms of CZA resistance in CRPA isolates from Ningbo, China.

A total of 279 non-duplicate clinical CRPA isolates (2022–2024) were classified as CZA-resistant (CZA-R, n = 68) or CZA-susceptible (CZA-S, n = 211). Carbapenemase genes were detected by PCR, clonality via MLST, biofilm formation by crystal violet assay, and efflux pump expression (mexA, mexC, mexE, mexY) via qRT-PCR. WGS was performed on selected isolates.

The CZA resistance rate was 24.37%. Risk factors included recent trauma, prior antibiotic exposure, central venous catheterization, and drainage tube placement (all p < 0.05). The CZA-R group showed higher recurrence (13.2% vs. 4.3%, p = 0.029) and lower clinical improvement (67.6% vs. 77.3%, p = 0.029). blaNDM
 prevalence was higher in CZA-R (7.4% vs. 0.5%, p = 0.003), and ST1076 was the predominant clone (29.3%), with higher representation in CZA-R (40.0%). Horizontal gene transfer mediated blaNDM
 spread. CZA-R isolates exhibited enhanced biofilm formation (p < 0.001) and mexA upregulation (2.04-fold, p = 0.007).

Our findings indicate a high prevalence of CZA resistance among CRPA isolates in Ningbo, driven by multiple mechanisms including blaNDM
 carriage, enhanced biofilm formation, and overexpression of efflux pumps. The dissemination of the high-risk clone ST1076 underscores the need for strengthened infection control measures to curb its spread. These findings provide important insights for optimizing infection control and treatment strategies against CRPA infections in this region.

## Linked entities

- **Genes:** mexA (multidrug resistance protein MexA) [NCBI Gene 877855], mexC (resistance-nodulation-cell division (RND) multidrug efflux membrane fusion protein MexC) [NCBI Gene 881078], mexE (resistance-nodulation-cell division (RND) multidrug efflux membrane fusion protein MexE) [NCBI Gene 880212], mexY (multidrug efflux RND transporter permease subunit MexY) [NCBI Gene 77221396]
- **Chemicals:** ceftazidime/avibactam (PubChem CID 90643431)
- **Species:** Pseudomonas aeruginosa (taxon 287)

## Full-text entities

- **Diseases:** infection (MESH:D007239), trauma (MESH:D014947)
- **Chemicals:** CZA (MESH:C000595613), Carbapenem (MESH:D015780)
- **Species:** Pseudomonas aeruginosa (species) [taxon 287]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12583027/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12583027/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC12583027/full.md

---
Source: https://tomesphere.com/paper/PMC12583027